What Florida Patients Should Know About Ozempic and Gastroparesis

Latest update (2026-01)

FDA enforcement record (Ongoing): Presence of Particulate Matter: Hair was found in a prefilled syringe. [source]

From General Health Information to Specialized Legal Guidance

If you're experiencing persistent nausea, vomiting, or abdominal pain while taking Ozempic, you may be concerned about gastroparesis. Medical literature has long recognized that certain diabetes medications can affect gastric motility, and recent case reports are shedding new light on this potential side effect. This page explains what current studies and FDA reports say about the link between Ozempic and gastroparesis.

Understanding Ozempic and Its Gastrointestinal Effects

Ozempic (semaglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist approved for the management of type 2 diabetes. Its mechanism of action includes slowing gastric emptying, which can contribute to gastrointestinal adverse effects. Gastroparesis is a condition characterized by delayed gastric emptying in the absence of mechanical obstruction, leading to symptoms such as nausea, vomiting, early satiety, and abdominal pain. The clinical presentation of gastroparesis can overlap with common gastrointestinal side effects of Ozempic, making diagnosis challenging. Clinical data from placebo-controlled trials indicate that gastrointestinal adverse reactions occur significantly more frequently among patients receiving Ozempic compared to placebo. In pooled trials, gastrointestinal adverse reactions were reported in 15.3% of placebo patients, 32.7% of those on Ozempic 0.5 mg, and 36.4% of those on Ozempic 1 mg (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). The majority of nausea, vomiting, and diarrhea episodes occurred during dose escalation. Discontinuation due to gastrointestinal adverse reactions was higher in Ozempic-treated patients (3.1% for 0.5 mg and 3.8% for 1 mg) compared to placebo (0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). In a trial comparing Ozempic 1 mg and 2 mg, gastrointestinal adverse reactions occurred in 30.8% of patients on 1 mg and 34.0% of those on 2 mg (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). Additional gastrointestinal adverse reactions reported at frequencies below 5% include dyspepsia (placebo 1.9%, Ozempic 0.5 mg 3.5%, Ozempic 1 mg 2.7%), eructation (0%, 2.7%, 1.1%), flatulence (0.8%, 0.4%, 1.5%), gastroesophageal reflux disease (0%, 1.9%, 1.5%), and gastritis (0.8%, 0.8%, 0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). These symptoms overlap with those of gastroparesis, but the label does not specifically list gastroparesis as an adverse reaction.

The Link Between Ozempic and Gastroparesis

The mechanistic pathway linking Ozempic to gastroparesis involves its action as a GLP-1 receptor agonist. GLP-1 receptors are expressed in the gastrointestinal tract, and activation delays gastric emptying. This pharmacodynamic effect is intended to reduce postprandial glucose excursions but can become pathological in some patients, leading to symptomatic gastroparesis. The timeline between exposure and documented harm is variable; gastrointestinal symptoms often emerge during dose escalation, but chronic use may lead to persistent delayed gastric emptying. The label notes that the majority of nausea, vomiting, and diarrhea occurred during dose escalation (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166), suggesting an early onset for many patients. However, some individuals may develop symptoms later or experience worsening over time. Regarding the adequacy of warnings, the Ozempic label includes a section on gastrointestinal adverse reactions but does not explicitly mention gastroparesis as a potential complication. The label states that gastrointestinal adverse reactions occurred more frequently with Ozempic than placebo and that discontinuation rates were higher (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). It also lists dyspepsia, gastroesophageal reflux disease, and gastritis as adverse reactions (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). However, the absence of a specific warning for gastroparesis may leave patients and healthcare providers unaware of this risk. For affected patients, this gap in labeling could be relevant in legal contexts, as it may be argued that the manufacturer did not adequately warn of the potential for gastroparesis.

Legal Considerations for Florida Patients

Attorney-related considerations for affected patients include the need to establish a causal link between Ozempic use and the development of gastroparesis. This requires medical documentation of symptoms consistent with gastroparesis, diagnostic confirmation (e.g., gastric emptying study), and exclusion of other causes. The timeline between exposure and symptom onset is critical; patients who developed gastrointestinal symptoms during dose escalation or after prolonged use may have stronger claims. Legal evaluation should also consider whether the manufacturer's warnings were sufficient to alert prescribers and patients to the risk of gastroparesis. The label's focus on nausea, vomiting, and diarrhea without naming gastroparesis could be a point of contention. In summary, Ozempic is associated with a range of gastrointestinal adverse reactions, including symptoms that overlap with gastroparesis. The drug's mechanism of delaying gastric emptying provides a plausible link to gastroparesis, though the label does not specifically warn of this condition. Patients who experience persistent gastrointestinal symptoms while on Ozempic should seek medical evaluation for gastroparesis. For those considering legal action, documentation of the timeline and severity of symptoms, along with expert medical testimony, will be essential.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the connection between Ozempic and gastroparesis?

Ozempic (semaglutide) is a GLP-1 receptor agonist that slows gastric emptying. This mechanism can lead to symptoms of gastroparesis, such as nausea, vomiting, and abdominal pain. Clinical trials show higher rates of gastrointestinal adverse reactions in Ozempic users compared to placebo (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166).

Does the Ozempic label warn about gastroparesis?

No, the Ozempic label does not specifically list gastroparesis as an adverse reaction. It mentions gastrointestinal side effects like nausea, vomiting, and diarrhea, but does not explicitly warn of gastroparesis (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166).

What should I do if I developed gastroparesis after taking Ozempic?

Seek medical evaluation for a formal diagnosis, including a gastric emptying study. Document your symptoms and timeline of Ozempic use. Consult with an attorney experienced in pharmaceutical litigation to discuss your legal options.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Ozempic exposure and a confirmed Gastroparesis diagnosis may request an independent eligibility review. [Begin Assessment]

References

Ozempic Prescribing Information - DailyMed

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.